



The Xarelto[®] Legacy

Experience across 4 indications

Xarelto[®] is indicated for:



Prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate.



Treatment of VTE (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.



Prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery.

10 mg, 15 mg, 20 mg



Prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD).

2.5 mg, in combination with 75 mg–100 mg acetylsalicylic acid (ASA)

 **Xarelto[®]**
rivaroxaban

Global experience




Launched in

114

COUNTRIES²

Xarelto® – Trust in our 11 years of experience



Xarelto® – Commitment to ongoing clinical research³



98 ongoing clinical trials
worldwide³



~844,000


patients projected to be
enrolled in these clinical trials³

The initiation of ongoing clinical trials intended to evaluate the efficacy and/or safety of Xarelto®

- Target Enrollment: N=2,500
Factor XA - Inhibition in Renal Patients with Non-valvular Atrial Fibrillation – Observational Registry (XARENO)
- Target Enrollment: N=10,000
Xarelto® + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis – a Non-Interventional Study (XATOA)
- Target Enrollment: N=450
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients – a Randomized Phase III Study (CONKO)

Xarelto® – A legacy of commitment to clinical research and patient care


Xarelto[®]: Trust in our experience



11 years
of experience

Launched in

114
countries²



62 million

patients treated in clinical practice worldwide
across all **four indications**^{2†}

[†] Xarelto[®] is indicated for the treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE; the prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate; the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery; and the prevention of stroke, myocardial infarction (MI) and cardiovascular (CV) death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD).¹



98

ongoing clinical trials
worldwide³



~844,000

patients projected to be
enrolled in these clinical trials³

Please consult the Xarelto® Product Monograph at www.bayer.ca/omr/online/xarelto-pm-en.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-265-7382.

References:

1. Xarelto® (rivaroxaban tablet) Product Monograph. Bayer Inc. September 20, 2019.
2. Data on file. IQVIA MIDAS, Database Quarterly Sales Q3 2019. Bayer Inc.
3. ClinicalTrials.gov. Last accessed November 27, 2019.



© TM see www.bayer.ca/tm-mc
© 2020, Bayer Inc.



XO482E
PP-XAR-CA-0535-1

